| |
 |
Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
|
| |
|
pp.1822-1824 (3) Authors: Raymond M. Schiffelers, Karin E. de Visser
|
| |
|
|
| |
|
Targeted Delivery of Anti-Inflammatory Agents to Tumors
|
| |
|
pp.1825-1843 (19) Authors: Maria Coimbra, Sylvia A. Kuijpers, Sebastiaan P. van Seters, Gert Storm, Raymond M. Schiffelers
|
| |
|
|
| |
|
Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
|
| |
|
pp.1844-1853 (10) Authors: Karin E. de Visser, Jos Jonkers
|
| |
|
|
| |
|
III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
|
| |
|
pp.1854-1867 (14) Authors: Mitsuko Furuya, Yoshikazu Yonemitsu, Ichiro Aoki
|
| |
|
|
| |
|
Mast Cells as Target in Cancer Therapy
|
| |
|
pp.1868-1878 (11) Authors: Tom Groot Kormelink, Abulikemu Abudukelimu, Frank A. Redegeld
|
| |
|
|
| |
|
Regulatory T Cells: Major Players in the Tumor Microenvironment
|
| |
|
pp.1879-1892 (14) Authors: Marc Beyer, Joachim L. Schultze
|
| |
|
|
| |
|
Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm
|
| |
|
pp.1893-1917 (25) Authors: Peng Zhan, Xinyong Liu
|
| |
|
|
| |
|
Scientific and Clinical Challenges in Sepsis
|
| |
|
pp.1918-1935 (18) Authors: Luis Ulloa, Michael Brunner, Laura Ramos, Edwin A. Deitch
|
| |
|
|
